This Startup Wants To Catch Cancer In Its Early Days – BuzzFeed News


A race is on among Silicon Valley startups to catch cancers
before they turn deadly. Victory will come for the winners in a
drop of blood — a sample serving as a long-sought “liquid
biopsy” for cancer.

One contestant is Freenome of South San Francisco, California,
which announced on Wednesday that it has raised $65 million to
test their experimental liquid biopsy and move it closer to
commercialization.

CEO Gabriel Otte says Freenome is most interested in preventing
cancer in the first place. “We see these screenings as a
catch-all, first line of defense you might be able to take, as
easy as doing a yearly physical,” he told BuzzFeed News.

Freenome declined to comment on its valuation, but a source
familiar with the startup told BuzzFeed News that it is worth
about $210 million after the round. Vaunted venture capital
firm Andreessen Horowitz led the investment. Other backers
included Peter Thiel’s Founders Fund, Asset Management
Ventures, Polaris, Data Collective, Eric Schmidt’s Innovation
Endeavors, Spectrum 28, Charles River Ventures and Google
Ventures.

The last is a notable investor since Google’s venture capital
arm has backed Grail, a Freenome competitor. Grail, a spin-out
of the DNA-sequencing giant Illumina, said in January that it
plans to raise
more than $1 billion to fund large-scale clinical trials.

The liquid biopsy side of the biotech industry is heating up:
While Grail and Freenome are developing liquid biopsy tests
that can detect early-stage cancer, others, led by Guardant
Health, are pursuing tests that do something different: they
track the progress of a patient’s diagnosed tumor.

These claims might sound similar to those of Theranos, which
once said that it could test tiny vials of blood for dozens of
conditions and has since had two of its lab licenses
revoked. In contrast, Freenome and its kind are restricting
their focus to cancer. The 25-person startup has not published
data about how its technology works, but says that it will,
along with the results of its current clinical trials, when
those tests conclude.

View this image ›

Freenome cofounders CEO Gabriel
Otte and Chief Operating Officer Riley Ennis.
Courtesy
/ Freenome

ID: 10615723

Traditionally, doctors and scientists look for cancer DNA in a
tissue sample from an actual tumor — but a “tissue biopsy,” as
it’s called, can be relatively expensive and invasive.
Depending on where the tumor is in the body, it can require
surgery.

“I hope that ultimately, if companies like Freenome are
successful in really confirming their diagnostic potential, we
might move toward an era where we obliviate the need for CT
scans, PET scans, MRIs and other radiographic tests, which are
all very, very costly,” said Sumanta Pal, an associate
professor and co-director of the Kidney Cancer Program at the
City of Hope Comprehensive Cancer Center, and an expert with
the American Society of Clinical Oncology.

In contrast to such scans, liquid biopsy companies are seeking
to harness a discovery that’s been around for less than a
decade, which is that tiny amounts of DNA from cancerous cells
are traceable in blood. The challenge, Pal says, is that liquid
biopsies involve very small amounts of blood, and tiny, hard to
detect DNA fragments.

But thanks to advancements in DNA-sequencing, these microscopic
gene fragments are getting easier to observe. And Freenome
wants to detect cancer by way of analyzing DNA fragments spewed
out by immune cells when they die, which happens as often as
hourly. Those fragments can contain changes that indicate the
cells were trying to attack a tumor, Otte said.

Otte and his cofounder, Riley Ennis, say that when it comes to
four types of tumors — breast, lung, colorectal, and prostate —
their technology is more accurate than the standard screening
test for each (mammograms for breast cancer, for instance).
It’s been tested, the founders say, on “thousands” of samples
from patients who thought they were healthy at the time of the
biopsy, and went on to develop cancer within a year or two.

“We’re not necessarily saying our blood test is going to
directly replace invasive biopsies,” Otte said. Rather, a
tissue biopsy “might be the next step you might take if a blood
test came back positive for a certain kind of cancer of a
certain kind of tissue.”

Otte declined to estimate when the test will be available at
your doctor’s, but the primary challenge for Freenome — and all
other companies in the field — will be proving that it’s
accurate.
A handful of studies have compared the sequencing results
of tissue and liquid biopsies that are currently on the market,
and found that the tests can vary in which mutations they
identify and which drugs they recommend.

A related and also significant hurdle will be getting insurance
reimbursement for these tests, so patients aren’t scared away
by a high price tag. Otte says that the company is in “early”
conversations with commercial insurance payers and the Centers
for Medicaid Services.

For Otte, the race to develop a test is especially personal:
his father has prostate cancer and his grandfather,
metastasized cancer. Otte watched both of them endure long
waits between getting tests done and waiting for the results.

For his father, “there was an extended period of time where he
wasn’t sure if he had cancer or not,” he said. “That’s
frightening for anybody, and gives you an indication of how
insufficient the diagnosis process is right now.”



Source link